Coherus BioSciences Management to Present at BMO’s Prescriptions for Success Healthcare Conference
December 01 2017 - 9:00AM
Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced that senior
management will be participating in a fireside chat at the BMO
Prescriptions for Success Healthcare Conference on Thursday,
December 14, 2017 at 1:30 p.m. EST being held in New York, NY.
The audio portion of the presentations will be available on the
investors page of the Coherus BioSciences website at
http://investors.coherus.com.
About Coherus BioSciences,
Inc.Coherus is a leading pure-play, global biosimilar
company that develops and commercializes high-quality therapeutics
for major regulated markets. Biosimilars are intended for use in
place of existing, branded biologics to treat a range of chronic
and often life-threatening diseases, with the potential to reduce
costs and expand patient access. Composed of a team of proven
industry veterans with world-class expertise in process science,
analytical characterization, protein production, sales &
marketing and clinical-regulatory development, Coherus is
positioned as a leader in the global biosimilar marketplace.
Coherus is advancing three late-stage clinical products towards
commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-1420
(adalimumab biosimilar), CHS-0214 (etanercept biosimilar), and
CHS-3351 (ranibizumab biosimilar) as well as developing a robust
pipeline of future products in four therapeutic areas, oncology,
immunology (anti-TNF), ophthalmology and multiple sclerosis. For
additional information, please visit www.coherus.com.
CONTACT:Patrick O'BrienSenior Vice President, Investor
RelationsCoherus BioSciences, Inc.pobrien@coherus.com+1 (650)
649-3527
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Apr 2023 to Apr 2024